GSK reveals new US patient assistance programs

18 December 2006

UK headquartered drugs giant GlaxoSmithKline has expanded its patient assistance programs in the USA, offering its retail prescription medicines for free to eligible low-income Medicare Part D participants. Beginning January 1, 2007, the company's new patient assistance program GSK Access will provide free medicines to eligible Part-D-enrolled senior and disabled patients who have spent at least $600 of their own money on outpatient medicines. GSK also plans to offer its existing patient assistance program for oncology medicines to Medicare Part D participants who reach the same $600 spending threshold.

"Even though the Medicare Part D plans have been a great success for many, we know that there are still patients who don't qualify for the government subsidies and may need help in getting their medicines. We believe GSK Access can be a real benefit to these patients," said Chris Viehbacher, president of GSK's US Pharmaceuticals business.

Mr Viehbacher added: "with our $600 spending threshold, most eligible patients can get their GSK medicines for free before they reach the gap in Medicare coverage known as the 'donut hole'."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight